XFRA CAPITAL ADJUSTMENT INFORMATION

XFRA CAPITAL ADJUSTMENT INFORMATION - 31.05.2024

Das Instrument 8VY DK0061031895 SCANDION ONC. DK-,0735 EQUITY wird ex Kapitalmassnahme gehandelt am 31.05.2024
The instrument 8VY DK0061031895 SCANDION ONC. DK-,0735 EQUITY is traded ex capital adjustment on 31.05.2024

Das Instrument ZHY KYG989761062 ZHOU HEI YA HLDG -,000001 EQUITY wird cum Kapitalmassnahme gehandelt am 31.05.2024 und ex Kapitalmassnahme am 03.06.2024
The instrument ZHY KYG989761062 ZHOU HEI YA HLDG -,000001 EQUITY is traded cum capital adjustment on 31.05.2024 and ex capital adjustment on 03.06.2024

Das Instrument 36M US82489T1043 SHOCKWAVE MEDICAL DL-,001 EQUITY wird cum Kapitalmassnahme gehandelt am 31.05.2024 und ex Kapitalmassnahme am 03.06.2024
The instrument 36M US82489T1043 SHOCKWAVE MEDICAL DL-,001 EQUITY is traded cum capital adjustment on 31.05.2024 and ex capital adjustment on 03.06.2024

Das Instrument 0VU1 KYG5700Y2097 LUFAX HLDG.L. A DL-,00001 EQUITY wird cum Kapitalmassnahme gehandelt am 31.05.2024 und ex Kapitalmassnahme am 03.06.2024
The instrument 0VU1 KYG5700Y2097 LUFAX HLDG.L. A DL-,00001 EQUITY is traded cum capital adjustment on 31.05.2024 and ex capital adjustment on 03.06.2024

Das Instrument E17 CA2927661025 ENERPLUS CORP. EQUITY wird ex Kapitalmassnahme gehandelt am 31.05.2024
The instrument E17 CA2927661025 ENERPLUS CORP. EQUITY is traded ex capital adjustment on 31.05.2024

Das Instrument 1YG SE0005003654 MENDUS AB EQUITY wird cum Kapitalmassnahme gehandelt am 31.05.2024 und ex Kapitalmassnahme am 03.06.2024
The instrument 1YG SE0005003654 MENDUS AB EQUITY is traded cum capital adjustment on 31.05.2024 and ex capital adjustment on 03.06.2024

Das Instrument GDO3 CA77536Q2027 ROGUE RES INC. EQUITY wird cum Kapitalmassnahme gehandelt am 31.05.2024 und ex Kapitalmassnahme am 03.06.2024
The instrument GDO3 CA77536Q2027 ROGUE RES INC. EQUITY is traded cum capital adjustment on 31.05.2024 and ex capital adjustment on 03.06.2024

Zeit	Aktuelle Nachrichten
03.03.	Clean Energy Transition Inc.: transition.inc Announces Updated Mineral Resource Estimate for the Aurora Nickel Project,- 10.5M tonnes at an Average 0.44% Ni grade- Near-Surface Mineralization, in Timmins, Ontario	TORONTO, ON / ACCESS Newswire / March 3, 2025 / Clean Energy Transition Inc. (TSX-V:TRAN) ("transition.inc" or the "Company") is pleased to announce an updated Mineral Resource Estimate ("MRE") prepared... ► Artikel lesen
29.01.	Clean Energy Transition Inc.: transition.inc Posts Investor Update - Summarizing 2024 and Forecasts for 2025	Not for Distribution to U.S. News Wire Services or Dissemination in the United States TORONTO, ON / ACCESS Newswire / January 29, 2025 / Clean Energy Transition Inc. (TSX-V:TRAN) ("transition.inc" or... ► Artikel lesen
15.01.	Clean Energy Transition Inc: Clean Energy private placement
24.12.24	Clean Energy Transition Inc: Clean Energy closes $425,000 private placement
24.12.24	Clean Energy Transition Inc.: TRANSITION.INC Completes Non-Brokered Private Placement of Flow-Through Units	Not for Distribution to U.S. News Wire Services or Dissemination in the United States TORONTO, ON / ACCESSWIRE / December 23, 2024 / Clean Energy Transition Inc. (TSXV:TRAN) ("transition.inc" or the... ► Artikel lesen

Zeit

Aktuelle Nachrichten

03.03.

Clean Energy Transition Inc.: transition.inc Announces Updated Mineral Resource Estimate for the Aurora Nickel Project,- 10.5M tonnes at an Average 0.44% Ni grade- Near-Surface Mineralization, in Timmins, Ontario

TORONTO, ON / ACCESS Newswire / March 3, 2025 / Clean Energy Transition Inc. (TSX-V:TRAN) ("transition.inc" or the "Company") is pleased to announce an updated Mineral Resource Estimate ("MRE") prepared...
► Artikel lesen

29.01.

Clean Energy Transition Inc.: transition.inc Posts Investor Update - Summarizing 2024 and Forecasts for 2025

Not for Distribution to U.S. News Wire Services or Dissemination in the United States TORONTO, ON / ACCESS Newswire / January 29, 2025 / Clean Energy Transition Inc. (TSX-V:TRAN) ("transition.inc" or...
► Artikel lesen

15.01.

Clean Energy Transition Inc: Clean Energy private placement

24.12.24

Clean Energy Transition Inc: Clean Energy closes $425,000 private placement

24.12.24

Clean Energy Transition Inc.: TRANSITION.INC Completes Non-Brokered Private Placement of Flow-Through Units

Not for Distribution to U.S. News Wire Services or Dissemination in the United States TORONTO, ON / ACCESSWIRE / December 23, 2024 / Clean Energy Transition Inc. (TSXV:TRAN) ("transition.inc" or the...
► Artikel lesen

Zeit	Aktuelle Nachrichten
21.02.	Mendus - CADENCE trial enrols first patient	Mendus has announced that the first patient has been enrolled in the CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group (ALLG). This is a multi-centre, randomised, controlled... ► Artikel lesen
21.02.	Mendus (OMX: IMMU) notes first patient enrolment in the CADENCE trial	Mendus has announced that the first patient has been enrolled in the Phase II AMLM22-CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group. The trial is a multicentre, randomised... ► Artikel lesen
20.02.	Mendus - Vididencel on track in AML going into 2025	Mendus has reported its FY24 results, reflecting an active period. Lead programme, vididencel in acute myeloid leukaemia (AML), had encouraging data from the ADVANCE II trial in December, laying the... ► Artikel lesen
13.02.	Mendus - Focus firmly on pivotal-stage readiness in 2025	Mendus's FY24 results and subsequent management presentation highlighted its focus on advancing lead asset, vididencel, to pivotal-stage readiness. Backed by robust long-term monotherapy data from ADVANCE... ► Artikel lesen
13.02.	Mendus AB: Mendus AB Year-end Report 2024	Preparations for pivotal-stage readiness of vididencel in AML on trackThe hard work of the Mendus team to advance the company's lead product vididencel in acute myeloid leukemia (AML) continued to pay... ► Artikel lesen

Zeit

Aktuelle Nachrichten

21.02.

Mendus - CADENCE trial enrols first patient

Mendus has announced that the first patient has been enrolled in the CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group (ALLG). This is a multi-centre, randomised, controlled...
► Artikel lesen

21.02.

Mendus (OMX: IMMU) notes first patient enrolment in the CADENCE trial

Mendus has announced that the first patient has been enrolled in the Phase II AMLM22-CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group. The trial is a multicentre, randomised...
► Artikel lesen

20.02.

Mendus - Vididencel on track in AML going into 2025

Mendus has reported its FY24 results, reflecting an active period. Lead programme, vididencel in acute myeloid leukaemia (AML), had encouraging data from the ADVANCE II trial in December, laying the...
► Artikel lesen

13.02.

Mendus - Focus firmly on pivotal-stage readiness in 2025

Mendus's FY24 results and subsequent management presentation highlighted its focus on advancing lead asset, vididencel, to pivotal-stage readiness. Backed by robust long-term monotherapy data from ADVANCE...
► Artikel lesen

13.02.

Mendus AB: Mendus AB Year-end Report 2024

Preparations for pivotal-stage readiness of vididencel in AML on trackThe hard work of the Mendus team to advance the company's lead product vididencel in acute myeloid leukemia (AML) continued to pay...
► Artikel lesen

Zeit	Aktuelle Nachrichten
13.01.	Scandion Oncology A/S: Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer		Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. In this phase I/II... ► Artikel lesen

Zeit

Aktuelle Nachrichten

13.01.

Scandion Oncology A/S: Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer

Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. In this phase I/II...
► Artikel lesen

Zeit	Aktuelle Nachrichten
Mo	ZHOU HEI YA (01458): DATE OF BOARD MEETING
18.02.	ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN
10.02.	ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN
03.02.	ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN
22.01.	ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN

Zeit

Aktuelle Nachrichten

ZHOU HEI YA (01458): DATE OF BOARD MEETING

18.02.

ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN

10.02.

ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN

03.02.

ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN

22.01.

ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN